<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051034</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2018-1199</org_study_id>
    <nct_id>NCT04051034</nct_id>
  </id_info>
  <brief_title>Heat Therapy and Omega 3 on Cardio-Metabolic Health</brief_title>
  <official_title>Heat Therapy and Omega 3 on Metabolic and Cardiovascular Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, controlled studies are lacking which test the benefits of: 1) ω3 PUFA; and 2) heat
      therapy on improving vascular-metabolic-microbiota health in Hispanic American populations.
      The investigator's objective is to determine if this modality (heat therapy i.e., warm water
      immersion, hot tubs) combined with dietary interventions (increased fish and/or fish oil
      intake) may be feasible treatments to improve cardiovascular risk factors and reduced
      comorbidities in Hispanic populations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a double-blind, placebo-controlled design, participants will be randomized to the
      following experimental treatments:

        1. 4 g omega 3 daily for 12 weeks combined with 6 weeks of heat therapy

        2. Placebo pill daily for 12 weeks with 6 weeks of heat therapy (HT)

      non-obese healthy will only serve as controls and enroll in placebo and neutral control
      therapy conditions.

      HT will entail 14 consecutive days of 1.5 hours passive heating (increase internal
      temperature 1.2°C above baseline), followed by 4 weeks of HT, 3 days per week.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Placebo or Omega 3 supplementation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic flexibility</measure>
    <time_frame>Change from baseline to 12 week metabolic flexibility</time_frame>
    <description>Mixed meal tolerance test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiome</measure>
    <time_frame>Change from baseline to 12 week in the phyla, genus and species of gut bacteria</time_frame>
    <description>Stool microbiome diversity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short chain fatty acids</measure>
    <time_frame>Change from baseline to 12 week short chain fatty acids, acetate, propionate, and butyrate (C4).</time_frame>
    <description>Stool Short chain fatty acids</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular Health</measure>
    <time_frame>Change from baseline to 12 week vessel function</time_frame>
    <description>Brachial and skin flow mediated dilation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Omega 3 supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks: Active: 1.25 g capsules/ [1.25 g capsule contains min. 750 mg EPA + 250 mg DHA] with heat therapy increasing internal body temperature 1.2C above baseline for 90 min each bout..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks: Placebo: 1.25 g capsules/ [1.25-gram high oleic safflower oil capsule]with heat therapy increasing internal body temperature 1.2C above baseline for 90 min each bout..</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega 3</intervention_name>
    <description>Active: 1.25 g capsules/420 35-count bottles [1.25 g capsule contains min. 750 mg EPA + 250 mg DHA] and heat therapy, increase internal body temperature 1.2 C above baseline.
Placebo: 14,700 1.25 g capsules/420 35-count bottles [1.25-gram high oleic safflower oil capsule]</description>
    <arm_group_label>Omega 3 supplementation</arm_group_label>
    <other_name>Organic Technologies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Active: 1.25 g capsules [1.25-gram high oleic safflower oil capsule] and heat therapy, increase internal body temperature 1.2 C above baseline.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI&gt;30-40,

          -  fasting glucose 100-125,

          -  blood pressure 130-139/80-89,

          -  Hispanic American,

          -  age 18-65 years

        Exclusion Criteria:

          -  non-Hispanic,

          -  BMI&lt;30, &gt;40,

          -  fasting glucose &lt;100, &gt;125,

          -  blood pressure &lt;130,&gt;139 systolic, &gt;90 diastolic,

          -  age &lt;18, &gt;65 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Rivas, Ph.D.</last_name>
    <phone>806-834-8563</phone>
    <email>eric.rivas@ttu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eric Rivas</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Rivas, Ph.D.</last_name>
      <phone>806-834-8563</phone>
      <phone_ext>8068348563</phone_ext>
      <email>eric.rivas@ttu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eric Rivas</last_name>
      <phone>8068348563</phone>
      <phone_ext>8068348563</phone_ext>
      <email>eric.rivas@ttu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Tech University</investigator_affiliation>
    <investigator_full_name>Eric Rivas</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

